Stefan Geschwindner
Director Biophysics, AstraZeneca
Stefan Geschwindner is listed as Director Biophysics, AstraZeneca. B2DB records 2 sessions at 1 conference in 2026, most recently Drug Discovery Chemistry Europe 2026 (November 2026). Speaks mainly at Hospitals and Health Care events.
Compiled from published conference agendas; not yet confirmed by Stefan. Is this you? Claim this profile.
- Sector: Hospitals and Health Care
About
Dr. Stefan Geschwindner is currently a Director at AstraZeneca R&D Gothenburg in Sweden where he is heading the Biophysics department within Discovery Sciences. His team is involved in every stage of early drug discovery, ranging from identifying and validating targets, finding and validating potential hits, generating leads (including fragments), and optimizing them, all the way to selecting candidate drugs. They employ diverse biophysical techniques to guide early drug discovery projects, assessing compound-target interactions and their mechanisms of action. Additionally, they play a pivotal role in advancing fragment-based lead generation strategies. He obtained his Ph.D. at the University of Frankfurt/Germany working predominantly with NMR to elucidate protein structures. After his Ph.D. he joined the Astra Structural Chemistry Laboratory with focus on protein engineering and characterization and helped to implement a variety of different biophysical techniques in the early dru
Sessions at 1 conference
Drug Discovery Chemistry Europe 2026 11 November 2026 – 12 November 2026
- Biophysical Approaches for Small Molecule Lead Generation Moderator · 11 November 2026
- Chairperson's Remarks: Biophysical & Computational Approaches For Lead Generation Chair · 10 November 2026
Spoke alongside
People who have shared a session with Stefan at events on B2DB.
- Juan Felix Espinosa Associate VP Biophysics, Early Molecule Discovery · Lilly 1 shared session
Others from AstraZeneca
- Paul Hudson President, AstraZeneca US and Executive Vice President, North America 5 sessions
- Shaun Grady Chair of AstraZeneca UK 4 sessions
- Olga Obrezanova Principal Scientist, Augmented Biologics Design 3 sessions
- Christof Jaeger Senior Director - Data Science & Modelling - Substance, Pharmaceutical Sciences 2 sessions
- Goran Dahl Associate Principal Scientist 2 sessions
- Melanie Leveridge Vice President Assays, Profiling & Cell Sciences 2 sessions
- Miranda Cooper Statistical Science Director 2 sessions
- Roger Kirby Senior Enterprise Architect 2 sessions
- Semra Kitchen Senior Director, Search & Evaluation, R&I 2 sessions
- Amberley Stephens Associate Principal Scientist 1 session
- Andre Verhoek HTA & Modelling Science Director 1 session
- Andreas Heddini Vice President Medical and Regulatory Affairs, Nordics 1 session